“Pick-a-winner” International Trial

Acute Myeloid Leukaemia (AML), an aggressive cancer of myeloid cells in the blood, is commonly treated by intensive chemotherapy, which is not tolerated in all patients.  As part of an exciting program aimed at improving outcomes of treatment in these patients, the LI-1 “Pick-a-winner” study evaluates new avenues for alternative therapies.  Relevant therapeutic questions were defined by the WHO and High-Risk Myelodysplastic Syndrome, and the study is funded by Leukaemia Lymphoma Research.

This trial already incorporates a few ‘firsts’ (first ever trial of an Hsp90 inhibitor (ganetespib) in AML and first randomized study of a SINE/CRM-1 inhibitor (selinexor), both carried out in Cardiff).  This is an open study in an international setting (Denmark, France, New Zealand and the UK).  Initial results are expected in 2015/16, though the study has already progressed to phase2b and may soon roll to phase 3.